TRAX
First Tracks Biotherapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$36.28
+5.28%Oct 15, 2026, 12:00 UTC
First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 common shares to institutional investors in a private placement at $32.75 per share, anticipating approximately $200 million in gross proceeds before fees and expenses.
Source:Oct 11, 2026, 20:00 UTC
First Tracks Biotherapeutics, Inc. announced that it will host an investor call and webcast on October 12, 2026, to review top-line data from Cohort 1 of its Phase 1b ANB033 trial in celiac disease.
Source:Aug 13, 2026, 13:07 UTC
First Tracks Biotherapeutics Inc reported its second-quarter financial results on Wednesday, showing a narrower loss compared to the prior year.
Source: